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Abstract
The purpose of this study was to develop an efficient and inexpensive method for the useful production of recombinant 
protein V antigen, an important virulence factor for Yersinia pestis. To this end, the synthetic gene encoding the V antigen 
was subcloned into the downstream of the intein (INT) and chitin-binding domain (CBD) from the pTXB1 vector using 
specific primers. In the following, the produced new plasmid, pTX-V, was transformed into E. coli  ER2566 strain, and the 
expression accuracy was confirmed using electrophoresis and Western blotting. In addition, the effects of medium, inducer, 
and temperature on the enhancement of protein production were studied using the Taguchi method. Finally, the V antigen 
was purified by a chitin affinity column using INT and CBD tag. The expression was induced by 0.05 mM IPTG at 25 °C 
under optimal conditions including TB medium. It was observed that the expression of the V-INT–CBD fusion protein was 
successfully increased to more than 40% of the total protein. The purity of V antigen was as high as 90%. This result indicates 
that V antigen can be produced at low cost and subjected to one-step purification using a self-cleaving INT tag.
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Introduction
Yersinia pestis has evolved from gastrointestinal patho-
gens and its antibiotic resistance can cause a dangerous 
disease, i.e., plague. Therefore, plague is still considered 
as a major threat to human health [1-3]. The human plague 
vaccine (USP) is a killed whole-cell plague bacilli that 
prevents plague infections through subcutaneous injection 
[4]. However, some reports have recently demonstrated the 
cytotoxic effects of whole-cell vaccines and their poor pro-
tection against virulent strains without capsules [5, 6]. The 
low calcium response (Lcr) of V antigen (LcrV) and the 
component 1 (F1) capsular antigen are the two important 
virulence factors which have been considered as vaccine 
candidates tested for their efficacy on humans and pri-
mates. LcrV is known as the virulence and multifunctional 
protein. This crucial protein has been shown to act at the 
level of secretion control by binding to other proteins in 
order to modulate the host immune response by altering 
cytokine production [7, 8]. Genetic engineering can be 
used to produce recombinant vaccines using different parts 
of Yersinia, such as V antigen and F1 [9, 10]. To this pur-
pose, the selection of effective methods to recombinant 
protein purification is a key factor of production. Highly 
purified recombinant proteins with the lowest and shortest 
time are the major problems for biotechnology research-
ers. Intein (INT) is the internal part of the protein that is 
derived from immature proteins during protein splicing 
process [11-13]. Since the discovery of the INT feature in 
1990, this fusion tag has been used in many biotechnol-
ogy applications. One of its wonderful applications is in 
the INT-tagged self-cleaving step to purify recombinant 
proteins [14, 15]. The INT tag is separated from the target 
protein by thiol induction, as well as by temperature and 
pH changes for one-step protein purification. The advan-
tage of this technique over other protein purification pro-
cedures is that the protease phase is eliminated, making 
the method economically affordable [16-18]. Thus, in the 
commercial pTXB1 and pTWIN vectors, intein is fused to 
the chitin-binding domain (CBD). The expressed fusion 
protein can be ligated to the chitin beads and then, pH, 
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temperature changes, or thiol induction leads to cleav-
age and separation of the target protein from INT tag and 
CBD. Finally, the target protein can be purified from the 
column without any additional amino acid [19, 20]. On the 
other hand, the traditional reaction optimization method 
involves the influence of one variable factor at a time. 
This method requires costly, time-consuming, and labori-
ous experiments. Statistical methods including Response 
surface and Taguchi methodologies are usually used to 
optimize the effective factors in increasing the produc-
tion of recombinant proteins. In Response Surface method, 
the relationship between the independent factors and the 
effective response can be evaluated in designed experi-
ments to predict, with more tests than Taguchi approach 
[21, 22]. In turn, in Taguchi methodology, more variables 
and qualitative factors can be investigated [23, 24]. Gener-
ally, when the cost and time limitations make it difficult 
to perform more experiments in the optimization process 
and also when discrete or qualitative factors such as media 
culture types are investigated, Taguchi design is preferred 
in bench-scale fermenter [25].
In this work, the INT tag was used to purify V antigen 
from Y. pestis in order to develop a new purification strat-
egy for this important protein. In addition, detailed stud-
ies were conducted to find optimal conditions of tempera-
ture, medium, inducer concentrations, and overexpressed 
V-INT–CBD fusion protein using the Taguchi method.
Materials and Methods
Primer Designing and Amplification of V Antigen
To amplify the V antigen encoding sequence, specific prim-
ers were designed based on the V antigen gene sequence 
retrieved from Gene bank (Accession No. AF167310.1). The 
NdeI enzyme restriction site sequence was added to the for-
ward primer (5ʹ-GGT GGT CAT ATG ATT AGAG CCT AC 
GAAC-3ʹ) and SapI enzyme restriction site sequence was 
also added to the reverse primer (5ʹ-GGT GGT T GCTCT 
TCCGC ATT TAC CAG ACG TGT CAT C-3ʹ). The pET-V 
(pET28a containing the V antigen encoding sequence) was 
amplified using the polymerase chain reaction (PCR). The 
PCR mixture (25 μl) contained 1 × PCR buffer, 4 mM mag-
nesium sulfate, 300 mM of each dNTP, 40 pmol per primer, 
5 μl (1 ng) V antigen in pET28 vector, and 0.2 unit Pfu DNA 
polymerase (Fermentase). The amplification was performed 
using the Techne thermocycler, with initial denaturation at 
94 °C for 4 min, 35 cycles at 94 °C for 60 s, 30 s at 53 °C, 
and 90 s at 72 °C, and the final extension was performed at 
72 °C for 10 min. The PCR product was analyzed using 1% 
agarose gel electrophoresis.
Cloning of V Antigen in pTXB1 Vector
The PCR product was purified using a gel purification kit 
(bioneer). The PCR product and the pTXB1 vector (NEB 
#N6707, Biolab) were double-digested with SapI and NdeI 
enzymes and then ligated together with T4 DNA ligase. The 
cloning of V antigen in the pTXB1 vector was verified by 
restriction enzyme mapping.
The Expression and Purification of the Fusion 
Protein
After confirming the pTX-V construct (Fig. 1c), the plas-
mid was transformed into the competent  ER2566 strain of 
E. coli, prepared by the calcium chloride method [24]. 
The transformed bacteria were grown in a 1-l Lysogeny 
broth (LB) containing 100 μg/ml ampicillin at 37 °C in 
an air shaker (250 rpm) until the optical density (OD600) 
at 600 nm reached 0.5–0.6. Then, the T7 promoter was 
induced by 0.3 mM isopropyl β-d-1-thiogalactopyranoside 
(IPTG) at 16 °C for 16 h (to increase the soluble protein). 
The expression of V antigen was assessed by SDS-PAGE 
and Western blotting at different times using specific anti-
chitin-binding domain serum antibodies (NEB #S6654, New 
England Biolabs Inc.). The cells were harvested and resus-
pended in 100 ml of column buffer (20 mM Tris–HCl, pH 
8.0, 0.5 M NaCl) and the crude cell extracts were prepared 
by sonication for 10 cycles of 30 s (Hielscher Ultrasonic, 
Germany). The supernatant was separated from the cell 
debris by centrifugation at 12,000×g for 30 min at 4 °C and 
passed through a 1 × 10 cm column (Bio-Rad, Hercules, CA) 
containing 10 ml of chitin beads (NEB #S6651). The flow 
rate was 0.5 ml/min. After loading the supernatant on the 
column, the flow rate was increased to 2 ml/min, and the 
column was thoroughly washed with the column buffer until 
the eluted non-specific protein content reached a minimum. 
Thereafter, a column buffer containing 50 mM dithiothreitol 
(DTT) was slowly passed through the column, the flow was 
stopped, and the column was incubated at room temperature 
for 16 to 40 h. Each fraction (1 ml) containing V antigen was 
obtained by eluting the column with the column buffer. All 
samples were analyzed by SDS-PAGE using 12% Tris–gly-
cine gel. The protein concentration was estimated using the 
Bradford method. After purification, DTT was removed from 
the buffer and the protein was concentrated using a Millipore 
centricon tube.
Optimization of V Antigen Expression
The enhancement of recombinant protein production and 
subsequently, the purification of the target protein, the effects 
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of temperature on the induction (15, 20, and 25 °C), media 
(Terrific Broth or TB, contains tryptone 1.2%, yeast extract 
2.4%, and glycerol 0.5%; Supper Broth or SB which con-
tains tryptone 3%, yeast extract 2%, MOPS 1%, and Glucose 
2%; and 32Y which contains tryptone 0.8%, yeast extract 
3.2%, and NaCl 0.58% in 10 mM Tris–HCl, pH 7.6), and 
inducer concentration (0.05, 0.1 and 0.15 mM) were inves-
tigated using the Taguchi statistical method [20] (Table 1). 
The Taguchi method is used to evaluate the factors consid-
ered. This method allows the simultaneous study of differ-
ent effective factors and their interactions. For this purpose, 
the experiments were designed on the L9 orthogonal array 
(Table 2) based on which each proposed test condition was 
repeated twice. Then the results (final concentration of the 
recombinant protein) were analyzed using Minitab-16 soft-
ware. Taguchi uses analysis techniques that do not depend 
on a model that relates the response to the factor effects. 
Rather, it uses a calculated response average to identify fac-
tors and their levels that yield maximum quality or quantity 
of the considered response (in this research the amount of 
recombinant protein). To compute the average performance 
or mean effect of any factor, amount of recombinant protein 
of experiments related to any level of each parameter are 
added and divided by the number of such trials.  
Results
Genetic Construct of pTXB1‑ V
After the PCR reaction, the product was confirmed by the 
emergence of a 981 bp band on 1% agarose gel electropho-
resis at about 981 bp (Fig. 1a). To clone the V antigen in 
pTXB1, the PCR product of the previous step and pTXB1 
were digested by SapI and NdeI restriction enzymes, and 
Fig. 1  a Analysis of the PCR product with specific primers, pfu 
enzyme and pET-V plasmid as a template. 1—DNA Ladder 1 kb, 2 
and 3—PCR products at 60 °C and 57 °C. b Double digestion of pTX-
V using PstI/NdeI. 1—DNA Ladder 1 kb, 2—undigested pTXB1, 4—
undigested pTX-V, 3,5—double-digested pTX-V in the first and sec-
ond clones. c pTX-V constructs
Table 1  Factors and levels of study in Taguchi experiment
TB terrific broth (tryptone 1.2%, yeast extract 2.4%, glycerol 0.5%), 
SB Super Broth (tryptone 3%, yeast extract 2%, MOPS 1%, Glucose 
2%), 32Y (tryptone 0.8%, yeast extract 3.2%, NaCl 0.58% in Tris–
HCl 10 mM, pH 7.6)
Culture medium IPTG concentra-
tion (mM)
Induction tem-
perature (°C)
Sur-
face 
factor
TB 0.05 15 1
SB 0.1 20 2
32Y 0.15 25 3
Table 2  Suggested experiments based on the Taguchi method
Factor Type of culture 
medium
Inducer concentra-
tion (mM)
Induction 
temperature 
(°C)
1 TB 0.1 15
2 SB 0.05 15
3 32Y 0.15 15
4 TB 0.15 20
5 SB 0.1 20
6 32Y 0.05 20
7 TB 0.05 25
8 SB 0.15 25
9 32Y 0.1 25
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the product was ligated into the pTXB1. Two colonies were 
randomly selected and pTXB1-V double digestion was per-
formed using PstI and NdeI enzymes (we could not use SapI 
enzyme because this site was disrupted after cloning, and the 
restriction site of PstI is present on pTXB1 but not in the 
sequence of the cloned V antigen). According to Fig. 1b, the 
emergence of a 1772 bp band on 1% agarose gel electropho-
resis confirmed the production of a new plasmid pTXB1-V 
(Fig. 1c).
The Fusion Protein (V‑INT–CBD) Expression
The pTXB1-V plasmid was transferred into E. coli ER2566 
and induced by IPTG. The protein expression was assessed 
by using SDS-PAGE and Western blotting at 0 and 4 h post-
induction. A protein size of about 65-kDa confirmed the 
expression of V antigen together with INT and CBD (Fig. 2) 
in which the molecular weight of INT and CBD was about 
34 kDa and the molecular weight of V antigen was about 
33 kDa.
Purification of V Antigen
The V-INT–CBD fusion protein was purified using chitin 
beads affinity chromatography. To this end, the lysed cells 
were passed through a column packed with chitin beads. 
After washing and removal of non-specific proteins, most 
of the fusion precursors were attached to the resin due to 
the high affinity of CBD to chitin beads. A lysis buffer con-
taining 50 mM dithiothreitol (DTT) as a cleavage disulfide 
bond was added into the column and incubated at room 
temperature for 16 h to release V antigen. In this step, INT 
and CBD were bound to chitin column. Finally, to remove 
INT–CBD from the resin, a 2% SDS stripping buffer was 
flowed through, and CBD and INT (34 kDa) were eluted 
from the chitin resin. Figure 3 shows the purification step 
of V antigen with an INT tag on SDS-PAGE. The results of 
recombinant protein optimization using the Taguchi method 
are shown in Table 3. Table 4 shows the analysis of vari-
ance (ANOVA) for the responses of recombinant protein 
production carried out according to the factors’ contribution 
Table 3  The optimization results of cultivating conditions and induction in the production of V antigen based on orthogonal array
Factor Induc-
tion 
temp.
(°C)
Medium IPTG (mM) OD600 Dry weight
(g/l)
Total protein
(g/l)
Producing 
time (h)
Expression (%) Productivity
(g/l/h)
Recombinant 
protein (g/L)
1 15 TB 0.1 12 5.25 3.26 54 42.5 0.026 1.38
2 15 SB 0.05 6 2.76 1.77 54 47.8 0.015 0.83
3 15 32Y 0.15 6 2.76 1.8 54 48 0.015 0.86
4 20 TB 0.15 8 3.68 2.02 30 26.7 0.015 0.52
5 20 SB 0.1 5 2.3 1.33 30 37.8 0.017 0.49
6 20 32Y 0.05 5 2.3 1.36 30 39.2 0.016 0.52
7 25 TB 0.05 8.5 3.91 2.61 24 49.69 0.05 1.28
8 25 SB 0.15 7 3.22 1.96 24 40.77 0.03 0.78
9 25 32Y 0.1 8 3.68 2.02 24 26.69 0.02 0.52
Fig. 2  Expression analysis of recombinant  ER2566 harboring of pTX-V 
using SDS-PAGE (a) and Western blot (b). (1) Protein size marker, 
(2) after induction and (3) before induction
Fig. 3  Purification of V antigen using intein tag. Expression at zero 
time (1) and after four hours of induction (2), protein size marker (3), 
cell lysis (4), the output after passing the cell lysis from column (5), 
output of washing column with buffer (6), initial output after induc-
tion by cleavage buffer (7), purified protein after 40 h (8, 9, and 10), 
the chitin beads after cleavage step (11), output after striping step (12)
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by the Taguchi method. In addition, the optimal conditions 
were obtained by analyzing the final concentration of the 
recombinant fusion protein and the variance of productivity 
(ANOVA).
The average effect of the investigated four factors has 
been plotted in Fig. 4 for visual inspection. The higher the 
slope of the graph of each factor in these figures indicates 
the amount of factor effect on the amount of produced pro-
tein. Hence, it can be concluded that the type of medium 
had the greatest influence on the production of the recombi-
nant fusion protein. Also, the induction temperature had the 
greatest effect impact on the protein production, while IPTG 
concentration had the least effect (Fig. 4). Furthermore, the 
results showed that test 7 had the optimum conditions for 
the production of an INT-V antigen fusion protein in E. coli. 
Figure 5 shows the effect of different conditions including 
Table 4  Analysis of variance 
for the obtained results 
of recombinant protein 
optimization using Taguchi 
method
Factor DOF (f) Sum of Sqrs. (S) Variance (V) F ratio (F) Pur Sum (Sʹ) Percent P (%)
Temperature 2 0.412 0.206 11.207 0.375 41.626
Medium 2 0.316 0.158 8.584 0.279 30.928
IPTG 2 0.137 0.137 3.73 0.1 11.133
Others 2 0.035 0.017 16.313
Fig. 4  The mean effect of temperature induction (a), media (b), and 
inducer concentration (c) at different levels on the recombinant fusion 
protein production. To compute the average performance or mean 
effect of any factor, amount of recombinant protein of experiments 
related to any level of each parameter are added and divided by the 
number of such trials
Fig. 5  Coomassie brilliant blue staining of protein, expressed in dif-
ferent temperatures, IPTG concentrations and culture medium by 
Taguchi statistical method. Time zero before induction (1, 9), test 
level one (2), two (3), three (4), protein size marker (5), test level four 
(6), five (7), six (8), seven (10), eight (11) and nine (12)
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temperature, IPTG concentration, and medium on the V anti-
gen expression. After optimizing the production conditions, 
the cells were incubated in the cleavage buffer after incuba-
tion at 4 °C for 16 h to obtain a protein with a high purity of 
90% and a suitable efficiency, as shown in Fig. 6.
Discussion
There is no safe or effective plague vaccine. The World 
Health Organization classifies the plague as a recurrent 
disease and as a class A pathogen causing an epidemic 
disease [26]. Killed whole-cell vaccines can only prevent 
pests and live attenuated vaccines, making guinea pigs and 
mice immune to plague, although this vaccine has health 
problems for humans [27, 28]. Today, researchers empha-
size subunit vaccine development. For decades, humans 
have been focusing on two recombinant proteins, Yersinia 
pestis, F1 and V proteins, as vaccine candidates [9, 10]. In 
order to facilitate the purification of recombinant proteins, 
soluble and affinity tags, such as schistosomiasis glutathione 
S-transferase (GST), Escherichia coli maltose-binding pro-
tein (MBP), transcription termination anti-termination factor 
(NusA), and peptide tags, such as poly His and poly Arg, 
are often used [29-32]. Since the affinity tag can affect the 
activity and/or structure of the target protein, it is typically 
cleaved from the target protein by a protease. Therefore, 
the isolation of protease and target protein fusion markers 
requires some additional purification steps [33]. In addition, 
proteases are generally inefficient and non-specific, resulting 
in partially cleaved products. In an intein (INT)-based purifi-
cation system, a modified INT fusion that induces a cleavage 
reaction at one end is catalyzed between the chitin-binding 
domain (CBD) and the recombinant target protein [34]. 
Using the natural self-splicing mechanism of INT, genetic 
engineers are able to produce commercial INT vectors to 
obtain recombinant proteins that do not require enzymatic or 
cofactor removal labels [35]. The most important feature of 
INT tag in recombinant protein production is its self-cleav-
ability with the addition of amino acids at the end of the tar-
get protein [36]. Furthermore, this method does not require 
proteases enzyme and time consuming steps for the removal 
of target proteins. Wood and co-authors believed that this 
method combined with other methods not only reduces the 
time and cost of recombinant protein production but also 
improves the efficiency of the final product [17, 37, 38]. 
Co-expression of V antigen with a suitable carrier protein 
results in the protease being less susceptible to degradation 
during purification [39]. For this purpose, different expres-
sion systems are used to increase the production of V anti-
gen. V antigen with GST and INT–CBD was produced in a 
relatively fused form in 2000 using three expression systems 
and after cleavage and purification of the target protein, its 
final concentration was 25 (pGEX-5X-2), 31 (pGEX-6P-2), 
and 0.75 mg/l [40]. In the present study, we first cloned 
and optimized the expression and purification of V antigen 
in the pTXB1 vector containing the 28-kDa-INT tag and 
6-kDa-CBD. V antigen production was examined using the 
INT tag to assess the self-cleavage properties of INT and to 
optimize culture conditions to increase protein production. 
The results of the Taguchi method showed that the yield 
increased to 40% (1.28 g/l). Recent studies have also shown 
that the molecular weight of hybrid proteins increases by 
34 kD compared to the native protein, but it has no nega-
tive effect on protein expression. On the other hand, INT-
thiol induction demonstrated suitable V antigen purification 
(Fig. 5) and this strategy was used for large-scale production 
of proteins and INT self-cleavage can be performed at 4 °C 
without DTT. In summary, the pTX-V expression system can 
be used as a suitable substitute for the industrial production 
of vaccines against sub-units of plague.
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